Differential effects of 16α-hydroxyestrone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells

Journal of Molecular Endocrinology

Volumn 34, Issue 1, 2005, Pages 91-105

  Lewis, Joan S ^a   Thomas, T J ^a,c   Pestell, Richard G ^b   Albanese, Chris ^b   Gallo, Michael A ^a,b,c   Thomas, Thresia ^a,b,c  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 METHOXYESTRADIOL; ACTIVATING TRANSCRIPTION FACTOR 2; CYCLIC AMP; CYCLIN D1; ESTROGEN RECEPTOR; FULVESTRANT; 16 HYDROXYESTRONE; 16-HYDROXYESTRONE; 2-METHOXYESTRADIOL; ATF2 PROTEIN, HUMAN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DRUG DERIVATIVE; ESTRADIOL; ESTRONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSCRIPTION FACTOR;

ANALYSIS OF VARIANCE; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DNA SYNTHESIS; DRUG INHIBITION; GENE ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN DNA BINDING; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; REPORTER GENE; TRANSACTIVATION; WESTERN BLOTTING; BREAST TUMOR; DNA REPLICATION; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ACTIVATING TRANSCRIPTION FACTOR 2; BLOTTING, WESTERN; BREAST NEOPLASMS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIN D1; DNA REPLICATION; ENZYME ACTIVATION; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYESTRONES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; TRANSCRIPTION FACTORS;

EID: 14544273363     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/jme.1.01599     Document Type: Article

References (93)

1. Abdel-Hafiz HA, Heasley LE, Kyriakis JM, Avruch J, Kroll DJ, Johnson GL & Hoeffler JP 1992 Activating transcription factor-2 DNA-binding activity is stimulated by phosphorylation catalyzed by p42 and p54 microtubule-associated protein kinases. Molecular Endocrinology 6 2079-2089.
2. Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A & Pestell RG 1995 Transforming p21 ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. Journal of Biological Chemistry 270 23589-23597.
3. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, Beato M, Sica V, Bresciani F & Weisz A 1996 17β-Estradiol induces cyclin D1 gene transcription, p36D1-p34 cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 12 2315-2324.
4. Altucci L, Addeo R, Cicatiello L, Germano D, Pacilio C, Battista T, Cancemi M, Petrizzi VB, Bresciani F & Weisz A 1997 Estrogen induces early and timed activation of cyclin-dependent kinases 4, 5, and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus. Endocrinology 138 978-984.
5. Aronica SM, Kraus WL & Katzenellenbogen BS 1994 Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. PNAS 91 8517-8521.
6. Ball P, Knuppen R, Haupt M & Breuer H 1972 Interactions between estrogens and catechol amines. III. Studies on the methylationof catechol estrogens, catechol amines and other catechols by the catechol O-methyltransferase of human liver. Journal of Clinical Endocrinology and Metabolism 34 736-746.
7. Beier F, Lee RJ, Taylor AC, Pestell RG & LuValle P 1999 Identification of the cyclin D1 gene as a target of activating transcription factor 2 in chondrocytes. PNAS 96 1433-1438.
8. Berthois Y, Katzenellenbogen JA & Katzenellenbogen BS 1986 Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen responsive cells in culture. PNAS 83 2496-2500.
9. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C & Darnell JE Jr 1999 Stat3 as an oncogene. Cell 98 295-303.
10. Brown JR, Nigh E, Lee RJ, Ye, H, Thompson MA, Saudou F, Pestell RG & Greenberg ME 1998 Fos family members induce cell cycle entry by activitating cyclin D1. Molecular and Cellular Biology 18 5609-5619.
11. Brueggemeier RW, Bhat AS, Lovely CJ, Coughenour HD, Joomprabutra S, Weitzel DH, Vandre DD, Yusuf F & Burak WE Jr 2001 2-Methoxymethylestradiol: a new 2-methoxy estrogen analog that exhibits antiproliferative activity and alters tubulin dynamics. Journal of Steroid Biochemistry and Molecular Biology 78 145-156.
12. Carlisle DL, Devereux WL, Hacker A, Woster PM & Casero RA Jr 2002 Growth status significantly affects the response of human lung cancer cells to antitumor polyamine-analogue exposure. Clinical Cancer Research 8 2684-2689.
13. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, Fiorentino R, Varricchio L, Barone MV & Auricchio F 2001 PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO Journal 20 6050-6059.
14. Chinenov Y & Kerppola T 2001 Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 20 2438-2452
15. Cushman M, He HM, Katzenellenbogen JA, Lin CM & Hamel E 1995 Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. Journal of Medical Chemistry 38 2041-2049.
16. D'Amato RJ, Lin CM, Flynn E, Folkman J & Hamel E 1994 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. PNAS 91 3964-3968.
17. D'Amico M, Hulit J, Amanatullah DF, Zafonte BT, Albanese C, Bouzahzah B, Fu M, Augenlicht LH, Donehower LA, Takemaru K, Moon RT, Davis R, Lisanti MP, Shtutman M, Zhurinsky J, Ben-Ze'ev A, Troussard AA, Dedhar S & Pestell RG 2000 The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3 beta and cAMP-responsive element-binding protein-dependent pathways. Journal of Biological Chemistry 275 32649 32657.
18. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA & Sutherland RL 2003 Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocrine-Related Cancer 10 179-186.
19. Dubey RK, Gillespie DG, Zacharia LC, Rosselli M, Korzekwa KR, Fingerle J & Jackson EK 2000 Methoxyestradiols mediate the antimitogenic effects of estradiol on vascular smooth muscle cells via estrogen receptor-independent mechanisms. Biochemical and Biophysical Research Communications 278 27-33.
20. Falkenstein E, Tillmann HC, Christ M, Feuring M & Wehling M 2000 Multiple actions of steroid hormones - a focus on rapid, nongenomic effects. Pharmacological Reviews 52 513-556.
21. Filardo EJ, Quinn JA, Frackelton AR Jr & Bland KI 2002 Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Molecular Endocrinology 16 7084.
22. Fishman J & Martucci CP 1980 Biological properties of 16 alpha-hydroxyesterone: implications of estrogen physiology and pathophysiology. Journal of Clinical Endocrinology and Metabolism 51 611-615.
23. Foster JS & Wimalasena J 1996 Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Molecular Endocrinology 10 488-498.
24. Foster JS, Henley DC, Ahamed S & Wimalasena J 2001 Estrogens and cell-cycle regulation in breast cancer. Trends in Endocrinology and Metabolism 12 320-327.
25. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesanno R, Nawroth PP & Schwelgerer L 1994 The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature 368 237-239.
26. Fuqua A, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, O'Malley BW & McGuire WL 1991 Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Research 51 105-109.
27. Golebiewska J, Rozwadowski P, Spodnik JH, Knap N, Wakabayashi T & Wozniak M 2002 Dual effect of 2-methoxyestradiol on cell cycle events in human osteosarcoma 143B cells. Acta Biochimica Polonica 49 59-65.
28. Gupta S, Campbell D, Derijard B & Davis RJ 1995 Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267 389-393.
29. Gupta M, McDougal A & Safe S 1998 Estrogenic and antiestrogenic activities of 16α- and 2-hydroxy metabolites of 17β-estradiol in MCF-7 and T47D human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 67 413-419.
30. Guttridge DC, Albanese C, Reuther JY, Pestell RG & Baldwin AS 1999 NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Molecular Cell Biology 19 5785-5799.
31. Hai TW, Liu F, Coukos WJ & Green MR 1993 Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes and Development 3 2083-2090.
32. Henderson BE, Ross R & Berstein L 1988 Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Research 48 246-253.
33. Herber B, Truss M, Beato M & Muller R 1994 Inducible regulatory elements in the human cyclin D1 promoter. Oncogene 9 1295-1304.
34. Jefcoate CR, Liehr JG, Santen RJ, Sutter TR, Yager JD, Yue W, Santner SJ, Tekmal R, Demers L, Parley R, Naftolin F, Mor G & Berstein L 2000 Tissue-specific synthesis and oxidative metabolism of estrogens. Journal of the National Cancer Institute Monographs 27 95-112.
35. Katazenellenbogen BS, Montano MM, Ediger TR, Sun J, Ekena K, Laz Martini PG, McInerney EM, Delage-Mourrous R, Weis K & Katzenellenbogen JA 2000 Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Progress in Hormone Research 55 163-193.
36. Kawasaki H, Taira K & Yokoyama K 2000 Histone acetyltransferase (HAT) activity of ATF-2 is necessary for the CRE-dependent transcription. Nucleic Acids Symposium Series 44 259-260.
37. Kinoshita Y & Chen S 2003 Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha. Cancer Research 63 3546-3555.
38. Klauber N, Parangi S, Flynn E, Hamel E & D'Amato RJ 1997 Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Research 57 81-86.
39. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio B, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka R & Manolagas SC 2001 Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104 719-730.
40. Kumar AP, Garcia GE & Slaga TJ 2001 2-Methoxyestradiol blocks cell-cycle progression at G2/M phase and inhibits growth of human prostate cancer cells. Molecular Carcinogenesis 31 111-124.
41. Laudet V, Hanni C, Cell J, Catzeflis F & Stehelin D 1992 Evolution of the nuclear receptor gene superfamily. EMBO Journal 11 1003-1012.
42. Lee RJ, Albanese C, Stenger RJ, Watanabe G, Inghirami G, Haines GK, Webster M, Muller WJ, Brugge JS, Davis RJ & Pestell RG 1999 pp60 v-src induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. Journal of Biological Chemistry 274 7341-7350.
43. Lewis JS, Thomas TJ, Klinge CM, Gallo MA & Thomas T 2001 Regulation of cell cycle and cyclins by 16α-hydroxyestrone in MCF-7 breast cancer cells. Journal of Molecular Endocrinology 27 293-307.
44. Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, Price RH Jr, Pestell RG & Kushner PJ 2002 Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. Journal of Biological Chemistry 277 24353-24360.
45. Livingstone C, Patel G & Jones N 1995 ATF-2 contains a phosphorylation-dependent transcriptional activation domain. EMBO Journal 14 1785-1797.
46. Lottering ML, Haag M & Seegers JC 1992 Effects of 17 β-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Research 52 3926-3932.
47. Madrid LV, Mayo MW, Reuther JY & Baldwin AS Jr 2001 Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. Journal of Biological Chemistry 276 18934-18940.
48. Margeat E, Bourdoncle A, Margueron R, Poujol N, Cavailles V & Royer C 2003 Ligands differentially modulate the protein interactions of the human estrogen receptors alpha and beta. Journal of Molecular Biology 326 77-92.
49. Markaverich BM & Clark JH 1979 Two binding sites for estradiol in rat uterine nuclei: relationship to uterotropic response. Endocrinology 105 1458-1462.
50. Marquez DC & Pietras RJ 2001 Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 20 5420-5430.
51. Martucci CP & Fishman 1993 J P450 enzymes of estrogen metabolism. Pharmacological Therapy 57 237-257.
52. McKenna NJ & O'Malley BW 2002 Minireview: nuclear receptor coactivators - an update. Endocrinology 143 2461-2465.
53. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E & Auricchio F 1996 Tyrosine kinase/p21 reas/MAT-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO Journal 15 1292-1300.
54. Mooberry SL 2003 Mechanism of action of 2-methoxyestradiol: new developments. Drug Resistance Updates 6 355-361.
55. 1 to complete the cell cycle. PNAS 91 8022-8026.
56. Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schunemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M & Berrino F 2000 Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16 alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 11 633-640.
57. Nilsson S & Gustafsson JA 2002 Estrogen receptor action. Critical Reviews in Eukaryotic Gene Expression 12 237-257.
58. Pacilio C, Germano D, Addeo R, Altucci L, Petrizzi VB, Cancemi M, Cicatiello L, Salzano S, Lallemand F, Michalides RJ, Bresciani F & Weisz A 1998 Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens. Cancer Research 58 871-876.
59. Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ & Arnold A 1999 The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocrine Reviews 20 501-534.
60. Planas-Silva MD, Donaher JL & Weinberg RA 1999 Functional activity of ectopically expressed estrogen receptor is not sufficient for estrogen-mediated cyclin D1 expression. Cancer Research 59 4788-4792.
61. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. Journal of Biological Chemistry 272 10882-10894.
62. Pribluda VS, Gubish ER Jr, Lavallee TM, Treston A, Swartz GM & Green SJ 2000 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer and Metastasis Reviews 19 173-179.
63. Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B & Davis RJ 1996 MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Molecular and Cellular Biology 16 1247-1255.
64. Razandi M, Pedram A, Greene GL & Levin ER 1999 Cell membrane and nuclear estrogen receptors derive from a single transcript: studies of ERα and ERβ expressed in CHO cells. Molecular Endocrinology 13 307-319.
65. Recio JA & Merlino G 2002 Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 2 1000-1008.
66. Robertson JF 2001 Faslodex (ICI 182, 780), a novel estrogen receptor downregulator - future possibilities in breast cancer. Journal of Steroid Biochemistry and Molecular Biology 79 209-212.
67. Russo J, Hasan Laxeef M, Balogh G, Guo S & Russo IH 2003 Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. Journal of Steroid Biochemisty and Molecular Biology 87 1-25.
68. Sabbah M, Courilleau D, Mester J & Redeuilh G 1999 Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. PNAS 96 11217-11222.
69. Schumacher G & Neuhaus P 2001 The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. Journal of Cancer Research and Clinical Oncology 127 405-410.
70. Seegers JC, Aveling M-L, van Aswegen CH, Cross M, Koch F & Joubert WS 1989 The cytotoxic effects of estradiol-17β, catecholestradiols, and methoxyestradiols on dividing MCF-7 and HeLa cells. Journal of Steroid Biochemistry 32 797-809.
71. Shah N, Thomas TJ, Lewis JS, Klinge CM, Shirahata A, Gelinas C & Thomas T 2001 Regulation of estrogenic and nuclear factor kappa B functions by polyamines and their role in polyamine analog-induced apoptosis of breast cancer cells. Oncogene 20 1715-1729.
72. Shoulars K, Brown T, Alejandro MA, Crowley J & Markaverich BM 2002 Identification of nuclear type II [(3)H]estradiol binding sites as histone H4. Biochemical and Biophysical Research Communications 296 1083-1090.
73. Sicinski P & Weinberg RA 1997 A specific role for cyclin D1 in mammary gland development. Journal of Mammary Gland Biology and Neoplasia 2 335-342.
74. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R & Santen RJ 2002 Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Molecular Endocrinology 16 116-127.
75. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R & Santen RJ 2004 The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. PNAS 101 2076-2081.
76. Stoica GE, Franke TF, Wellstein A, Czubayko F, List HJ, Reiter R, Morgan E, Martin MB & Stoica A 2003 Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Molecular Endocrinology 17 818-830.
77. Suto A, Telang NT, Tanino H, Takeshita T, Ohmiya H, Osborne MP & Kubota T 1999 In vitro and in vivo modulation of growth regulation in the human breast cancer cell line MCF-7 by estradiol metabolites. Breast Cancer 6 87-92.
78. Sutherland RL & Musgrove EA 2004 Cyclins and breast cancer. Journal of Mammary Gland Biology and Neoplasia 9 95-104.
79. Teyssier C, Belguise K, Galtier F & Chalbos D 2001 Characterization of the physical interaction between estrogen receptor alpha and JUN proteins. Journal of Biological Chemistry 276 36361-36369.
80. Thomas T & Thomas TJ 1994 Regulation of cyclin B1 by estradiol and polyamines in MCF-7 breast cancer cells. Cancer Research 54 1077-1084.
81. Thomas T, Trend B, Butterfield JR, Janne OA & Kiang DT 1989 Regulation of ornithine decarboxylase gene expression in MCF-7 breast cancer cells by antiestrogens. Cancer Research 49 5852-5857.
82. Thomas T, Gallo MA & Thomas TJ 2004 Estrogen receptors as targets of drug development for breast cancer, osteoporosis and cardiovascular diseases. Current Cancer Drug Targets 4 483-499.
83. Uht RM, Anderson CM, Webb P & Kushner PJ 1997 Transcriptional activities of estrogen and glucocorticoid receptors are functionally integrated at the AP-1 response element. Endocrinology 138 2900-2908.
84. van Dam H, Withelm D, Herr I, Steffen A, Herrlich P & Angel P 1995 ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO Journal 14 1798-1811.
85. Waas WF, Lo HH & Dalby KN 2001 The kinetic mechanism of the dual phosphorylation of the ATF2 transcription factor by p38 mitogen-activated protein (MAP) kinase alpha. Implications for signal/response profiles of MAP kinase pathways. Journal of Biological Chemistry 276 5676-5684.
86. Wade CB, Robinson S, Shapiro RA & Dorsa DM 2001 Estrogen receptor (ER)alpha and ERbeta exhibit unique pharmacologic properties when coupled to activation of the mitogen-activated protein kinase pathway. Endocrinology 142 2336-2342.
87. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A & Schmidt EV 1994 Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369 669-671.
88. Watanabe G, Howe A, Lee RJ, Albanese C, Shu IW, Karnezis AN, Zon L, Kyriakis J, Rundell K & Pestell RG 1996 Induction of cyclin D1 by simian virus 40 small tumor antigen. PNAS 93 12861-12866.
89. Watanabe G, Albanese C, Lee RJ, Reutens A, Vairo G, Henglein B & Pestell RG 1998 Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1. Molecular and Cellular Biology 18 3212-3222.
90. Weatherman RV, Chang CY, Clegg NJ, Carroll DC, Day RN, Baxter JD, McDonnell DP, Scanlan TS & Schaufele F 2002 Ligand-selective interactions of ER detected in living cells by fluorescence resonance energy transfer. Molecular Endocrinology 16 487-496.
91. Yamakawa K & Arita J 2004 Cross-talk between the estrogen receptor-, protein kinase A-, and mitogen-activated protein kinase-mediated signaling pathways in the regulation of lactotroph prolileration in primary culture. Journal of Steroid Biochemistry and Molecular Biology 88 123-130.
92. Zhu BT & Conney AH 1998 Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Research 58 2269-2277.
93. Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ & Bernards R 1998 Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes and Development 12 3488-3498.